Debbie Baker

Debbie Baker is a retired Managing Director and Business Development leader at Oxford Finance LLC, a specialty finance firm that provides senior secured (venture) debt to life sciences and healthcare-services companies. It is worth flagging up front that the source record classifying her as an "Angel Investor" making "Seed Round" investments appears to be inaccurate: Baker's career was in debt financing / lending to commercial- and growth-stage healthcare companies, not early-stage equity angel investing.

Baker joined Oxford Finance Corporation in December 2010 as Director of Business Development, responsible for originating loan facilities for life science and medical device companies primarily across western North America. At the time she was hired, she already brought more than 30 years of financial-services experience, predominantly in the healthcare industry. Her prior roles included Executive Vice President at Capital Advisors Group (investment management for life science and medical device firms), Regional Business Development Director at Questpoint, Treasurer at MFS Intelenet, Assistant Treasurer at ASK Computer Systems, Vice President of Corporate Finance and Debt at Sierra Capital Companies, and Treasurer at Consolidated Capital (where she oversaw five public REITs and 22 real estate partnerships). Aggregator profiles list an MBA from the University of Denver's Daniels College of Business.

Over roughly eleven years at Oxford, Baker was credited internally with helping grow both the firm's loan portfolio and the Oxford brand in the western U.S. She retired around June 30, 2021, then remained with the firm in a consulting capacity through the end of 2021, after which she is listed as "retired" as Managing Director at Oxford Finance LLC.

Oxford Finance itself is a leading specialty lender that has operated for over 20 years, headquartered in Alexandria, Virginia, with offices in California, Massachusetts, and North Carolina. The firm has originated more than $8.5 billion in loans to over 500 companies, providing flexible senior debt as an alternative or complement to equity dilution for life sciences and healthcare-services borrowers.

• Provided senior secured debt (venture/growth debt) — not equity — to public and private life science, medical device, and healthcare-services companies.
• Focused origination on western North America, sourcing borrowers that needed non-dilutive capital to extend runway, fund commercialization, or bridge to milestones.
• Oxford's structural sweet spot: credit facilities historically from ~$500K–$40M in her early tenure, scaling to a firm-wide range of roughly $5M–$200M.
• Emphasis (per firm messaging) on flexible, creative financing solutions tailored to the cash-flow and milestone realities of healthcare companies — a lender's "yes" hinges on enterprise/asset quality, existing equity backing, and a credible path to value inflection, rather than on a pitch-deck vision.

No individual deals are publicly attributed to Baker personally. She operated as a loan originator / relationship lead, so her work is embedded in Oxford's broader portfolio rather than credited as named investments. At the portfolio level, Oxford Finance reports having originated $8.5B+ in loans to 500+ life science and healthcare companies. Specific borrower names tied to Baker's book of business are not disclosed in public sources.